MarketsandMarkets

Immunoassay Market (Technology, Analyzers, Reagents & Applications) Worth $19.1 Billion by 2018

The expanding use of immunoassays, increasing demand for high quality healthcare services, and rapidly increasing geriatric population are the major factors that drives the global market.

 
Repost This

Dallas, TX -- (SBWIRE) -- 01/14/2014 -- The "Immunoassay Market [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Applications (Infectious Diseases, Cancer, Endocrinology, Cardiology), End Users (Hospitals, Laboratory, Academics)] - Global Forecast to 2018" provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global immunoassays market along with the estimates and forecasts of the revenue and share analysis.

Do Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=436

Browse 118 market data tables with 86 figures spread through 421 pages and in-depth TOC on "Immunoassay Market"
http://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html

Early buyers will receive 10% customization on this report.

The global market is segmented by technology, application, product (analyzers and reagents), and end user. The global market, by technology, is further segmented into enzyme immunoassay, fluorescent immunoassay, chemiluminescence immunoassay, radioimmunoassay, and others. Enzyme immunoassay accounted for the largest share of the global market in 2012, owing to their long-term presence and high sensitivity. However, the chemiluminescence immunoassay market will see the highest growth in the next five years, which is attributed to the high-throughput and automation offered by CLIAs.

On the basis of application, the market has segments like oncology, infectious diseases, cardiology, bone and mineral, endocrinology, autoimmunity, toxicology, hematology (anemia), neonatal screening, and others. The infectious diseases segment commanded the largest share of 35.2% of the immunoassay market in 2012 due to the high specificity of immunoassay in diagnosing these diseases. Oncology will be the fastest-growing application owing to the high prevalence of cancer diseases worldwide and the development of a wide array of cancer biomarkers.

The immunoassay segment contributes about one-fourth to the IVD market and is valued at $13.0 billion in 2013. Immunoassay are characterized by high specificity, sensitivity, and low costs. It is estimated to be the second-fastest growing sector of IVD after molecular diagnostics. The immunoassay market will be driven by factors such as growing incidences of chronic and infectious diseases, increasing aging population, ongoing technological innovations, increasing demand for non-invasive diagnostic tools and techniques, and the identification and introduction of novel biomarkers. The availability of novel tests based on condition-specific markers and increasing adoption of immunoassay tests in emerging countries are also factors that exhibit growth opportunities for the immunoassay market. There is also an increasing demand for Lateral flow (LF) tests due to the need for immediate medical information and the demand for rapid test results, easy and convenient access, accuracy, and sensitivity. Thus LF tests are driving the immunoassays market.

Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Ortho Clinical Diagnostics (U.S.), Alere, Inc. (U.S.), Sysmex Corporation (Japan), and DiaSorin S.P.A. (Italy) are the key industry participants. The immunoassay market is dominated by established players and is consolidated, with the top 5 players occupying more than 80% of the market. The market offers huge barriers for new entrants as the industry demands high capital investments for R&D and testing and manufacturing of products. Moreover, companies have to follow stringent regulations to get product approvals in various countries.

Browse Related Reports:
Vendor Neutral Archive Market & PACS Market - VNA [On-premise Software, Hybrid & Cloud, Multi-Department & Multi-Site VNA] & Picture Archiving and Communication System [Enterprise, Cardiology & Radiology] - Global Forecast to 2018
http://www.marketsandmarkets.com/Market-Reports/vendor-neutral-archive-VNA-PACS-market-1255.html

Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013 – 2018)
http://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets